Scholarlink

<p>Immune thrombocytopenia (ITP) features autoantibody-mediated platelet clearance, but how inflammatory mediators impair thrombopoiesis remains less defined. Using single-cell and spatial transcriptomics, we identify a neutrophil–megakaryocyte axis in ITP marrow in which neutrophil-derived S100A8/A9 engages TLR4 and activates JNK/c-Jun signaling. This pathway represses the megakaryocyte master regulator GATA1 and constrains maturation. In primary CD34<sup>+</sup>-derived megakaryocyte cultures, ITP plasma reduces polyploidization, maturation-marker expression, and platelet-like particle release; tasquinimod treatment or TLR4 inhibition partially restores these endpoints. In active and passive ITP mouse models, tasquinimod improves platelet recovery, normalizes marrow megakaryocyte abundance, and dampens MAPK signatures. Together, these complementary data position neutrophils as contributors to thrombopoietic failure in ITP, connect marrow inflammation to defective platelet production, and nominate the S100A8/A9–TLR4–JNK/c-Jun axis as a therapeutic target. Modulating this pathway partially restores megakaryopoiesis and alleviates thrombocytopenia in vivo, supporting pharmacologic targeting of S100A8/A9–TLR4 signaling as a potential adjunct to ITP therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neutrophil-derived S100A8/A9 impairs megakaryocyte maturation in immune thrombocytopenia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Jiaqian Qi,
  • Meng Zhou,
  • Jie Yin,
  • Xiaofei Song,
  • Yan Zhang,
  • Haohao Han,
  • Xueqian Li,
  • Ziyan Zhang,
  • Yaqiong Tang,
  • Fei Yang,
  • Depei Wu,
  • Zhenyu Li,
  • Yue Han

摘要

Immune thrombocytopenia (ITP) features autoantibody-mediated platelet clearance, but how inflammatory mediators impair thrombopoiesis remains less defined. Using single-cell and spatial transcriptomics, we identify a neutrophil–megakaryocyte axis in ITP marrow in which neutrophil-derived S100A8/A9 engages TLR4 and activates JNK/c-Jun signaling. This pathway represses the megakaryocyte master regulator GATA1 and constrains maturation. In primary CD34+-derived megakaryocyte cultures, ITP plasma reduces polyploidization, maturation-marker expression, and platelet-like particle release; tasquinimod treatment or TLR4 inhibition partially restores these endpoints. In active and passive ITP mouse models, tasquinimod improves platelet recovery, normalizes marrow megakaryocyte abundance, and dampens MAPK signatures. Together, these complementary data position neutrophils as contributors to thrombopoietic failure in ITP, connect marrow inflammation to defective platelet production, and nominate the S100A8/A9–TLR4–JNK/c-Jun axis as a therapeutic target. Modulating this pathway partially restores megakaryopoiesis and alleviates thrombocytopenia in vivo, supporting pharmacologic targeting of S100A8/A9–TLR4 signaling as a potential adjunct to ITP therapy.